S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Regeneron to Report Second Quarter 2014 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2014|
|Sanofi and Regeneron Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis|
|Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission|
|Two-Year Results From Phase 3 VIVID-DME Trial of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema Show Sustained Improvement in Vision|
|Sanofi and Regeneron Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia|
|Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia|
|EYLEA® (aflibercept) Injection Receives FDA Approval for the Treatment of Diabetic Macular Edema (DME)|
|Robbins Arroyo LLP Is Investigating the Officers and Directors of Regeneron Pharmaceuticals, Inc. on Behalf of Shareholders|
|Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) to Ring The NASDAQ Stock Market Opening Bell|
|Regeneron Announces Submission of Application for EYLEA® (aflibercept) Injection in Japan for Macular Edema Following Branch Retinal Vein Occlusion|
Click above to view more mutual fund data and stats for regn - Regeneron Pharmaceuticals Inc.